Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2a Study of SQY51 in Duchenne Muscular Dystrophy
2022-500703-49-01Phase 2Authorised
- Sponsor
- SQY Therapeutics
- Start
- Nov 2022
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SQY51 in Duchenne muscular dystrophy (DMD), sponsored by SQY Therapeutics. Primary endpoints: Safety and tolerability of SQY51 and Extension phase primary objectives. Planned start Nov 2022; status: authorised.
02
Drugs
SQY51
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on 2022-500703-49-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500703-49-01.